Image - 8 November 2021

Vakona

License:: Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
By:: Press
File format:: .jpg
Size:: 2828 x 2121, 1.89 MB

Download

Topics

Tomas Ruuth
Press contact Head of PR & Communications PR & Communications tomas.ruuth@ubi.se 072-4024697 www.ubi.se

8 November 2021 07:57
Multimillion SEK investment in Vakona signals start of production

Three investors are backing Umeå-based pharmaceutical company Vakona with funding worth millions of SEK. “We are absolutely delighted and proud to have attracted this investment. It’s a reward for many years of hard work and takes us one step closer to clinical human trials”, says Gabriella Persson, CEO of Vakona.
2 March 2022 08:00
New acne medicine takes one step closer to market launch

Umeå-based pharmaceutical company Vakona has signed an agreement with French company GTP Tech to initiate the first manufacturing steps of its acne medicine. “Production is at a level of quality that enables the medicine to be used in human clinical trials. If all goes well the medicine should be on the market within five to seven years”, says Mats Strömqvist, CEO and Chairman of the Board of Vak